Answers are grounded in this paper and cite their sources.
606 Background: Neoadjuvant therapy (NAT) by combining polychemotherapy and HER2-targeted drugs has become the golden standard treatment for patients with early-stage Her2-positive breast cancer. Pathologic complete response (pCR) is a surrogate marker that predicts a favorable prognosis. Tumor infiltration lymphocytes (TILs) and immune profiling had been reported as a biomarker associated with the pCR. There are several types of immune cells such as monocytes, T and B cell; however, it’s uncertain which kind of immune cells and immune profile play the most important role to predict the pCR in Her2-positive breast cancer. Methods: We enrolled 188 breast cancer patients who were diagnosed of having stage I-III Her2-positive breast cancer. All patients received taxane in combination with Her2-targeted therapies. We performed RNA sequencing on the breast cancer samples which were collected before treatment. Immunohistochemical staining of immune markers were done, too. Results: 103 patients were treated with trastuzumab-based NAT and 85 patients were treated with dual-blockade (trastuzumab plus pertuzumab) based NAT. Among the clinical and tumor characteristics, high expression of Her2 and low expression of ESR1 were associated with the pCR (both p <0.01). Dual blockade therapy tended towards pCR, but lacked statistical significance. For the microenvironment, we deconvoluted the immune cells from the RNA-seq data to measure the cell populations. The proportion of immune cells was correlated to the TILs that was measured from the pathology slides (p<0.01). Both the TILs and the immune cell amounts from the RNA-seq were significantly associated with the pCR (both p<0.01). By the deconvoluted cell types, higher abundance of B cells was significantly associated with the pCR, compared to lower B cell amount (p<0.001). The total T cells, CD8 T cells and monocytes were trended to the pCR but not statistical significance. We then subgroup B cells into the mature B populations which express immunoglobulin genes and immature B populations which express RAG-1 gene without immunoglobulin. We found that only the mature B cells predicted the pCR and immature B cell didn’t. Multivariate logistic regression analysis adjusted for ESR1 expression, Her2 expression and dual blockade therapy, only the mature B cell independently predicted the pCR (odds ratio, 2.63; 95%CI, 1.34-5.16; p = 0.005). The total TILs by pathology slide and other immune cell types didn’t. In addition to pCR, the mature B cells were independently related to the superior recurrence-free survival by the multivariate Cox regression model after adjusting the ESR1 expression, Her2 expression, dual blockade therapy, TIL and immune cell types (hazard ratio, 0.32 ;95% CI, 0.11-0.98; p=0.047). Conclusions: Our result suggested that the mature B cell signature was more strongly associated with the pCR and recurrence-free survival than TILs.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: